JAK Inhibitors (e.g., Olumiant)
JAK inhibitors, such as Olumiant (Baricitinib), were initially developed to treat inflammatory and autoimmune diseases, including rheumatoid arthritis. Their role in alopecia areata treatment is based on blocking Janus kinase enzymes, which are key players in the pathway leading to the immune attack on hair follicles. By interfering with this pathway, JAK inhibitors can prevent hair loss and promote regrowth in cases of severe alopecia areata, offering hope to both men and women with this challenging condition.
Used for: Alopecia Areata